There are 2137 resources available
LBA11 - IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)
Presenter: Nadia Harbeck
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
159O - Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group
Presenter: Vincent De Jong
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Webcast
160O - Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)
Presenter: Andreas Schneeweiss
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
1913O - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
Presenter: Mimi Hu
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
1259O - A randomized phase II study of osimertinib with or without bevacizumab in advanced lung adenocarcinoma patients with EGFR T790M mutation (West Japan Oncology Group 8715L)
Presenter: Yukihiro Toi
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
LBA41 - LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours
Presenter: Zarnie Lwin
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1019O - Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Nehal Lakhani
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1020O - A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours
Presenter: Manish Sharma
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1160O - An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): An interim analysis
Presenter: Guillaume Nicolas
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
1257O - Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
Presenter: David Hong
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast